Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.

American journal of virology

Denniston E, Crewdson H, Rucinsky N, Stegman A, Remenar D, Moio K, Clark B, Higginbotham A, Keffer R, Brammer S, Horzempa J.
PMID: 28203321
Am J Virol. 2016;5(1):1-7. doi: 10.3844/ajvsp.2016.1.7. Epub 2016 Mar 03.

The inauguration of novel treatment strategies into the clinical setting faces a number of hurdles. In addition to treatment efficacy and safety, acceptance by doctors and patients is paramount to the success of novel therapies. Although viruses are the...

Cite
Denniston E, Crewdson H, Rucinsky N, et al. The Practical Consideration of Poliovirus as an Oncolytic Virotherapy. Am J Virol. 2016;5(1):1-7doi: 10.3844/ajvsp.2016.1.7.
Denniston, E., Crewdson, H., Rucinsky, N., Stegman, A., Remenar, D., Moio, K., Clark, B., Higginbotham, A., Keffer, R., Brammer, S., & Horzempa, J. (2016). The Practical Consideration of Poliovirus as an Oncolytic Virotherapy. American journal of virology, 5(1), 1-7. https://doi.org/10.3844/ajvsp.2016.1.7
Denniston, Elizabeth, et al. "The Practical Consideration of Poliovirus as an Oncolytic Virotherapy." American journal of virology vol. 5,1 (2016): 1-7. doi: https://doi.org/10.3844/ajvsp.2016.1.7
Denniston E, Crewdson H, Rucinsky N, Stegman A, Remenar D, Moio K, Clark B, Higginbotham A, Keffer R, Brammer S, Horzempa J. The Practical Consideration of Poliovirus as an Oncolytic Virotherapy. Am J Virol. 2016;5(1):1-7. doi: 10.3844/ajvsp.2016.1.7. Epub 2016 Mar 03. PMID: 28203321; PMCID: PMC5304422.
Copy Download .nbib Format: NLM
Adoptive T Cell Therapy Targeting CD1 and MR1.

Frontiers in immunology

Guo T, Chamoto K, Hirano N.
PMID: 26052329
Front Immunol. 2015 May 20;6:247. doi: 10.3389/fimmu.2015.00247. eCollection 2015.

Adoptive T cell immunotherapy has demonstrated clinically relevant efficacy in treating malignant and infectious diseases. However, much of these therapies have been focused on enhancing, or generating de novo, effector functions of conventional T cells recognizing HLA molecules. Given...

Cite
Guo T, Chamoto K, Hirano N. Adoptive T Cell Therapy Targeting CD1 and MR1. Front Immunol. 2015;6:247doi: 10.3389/fimmu.2015.00247.
Guo, T., Chamoto, K., & Hirano, N. (2015). Adoptive T Cell Therapy Targeting CD1 and MR1. Frontiers in immunology, 6247. https://doi.org/10.3389/fimmu.2015.00247
Guo, Tingxi, et al. "Adoptive T Cell Therapy Targeting CD1 and MR1." Frontiers in immunology vol. 6 (2015): 247. doi: https://doi.org/10.3389/fimmu.2015.00247
Guo T, Chamoto K, Hirano N. Adoptive T Cell Therapy Targeting CD1 and MR1. Front Immunol. 2015 May 20;6:247. doi: 10.3389/fimmu.2015.00247. eCollection 2015. PMID: 26052329; PMCID: PMC4440381.
Copy Download .nbib Format: NLM
Effect of GM-CSF, 1, 25-Dihydroxycholecalciferol (Vit.D) and All-Trans-Retinoic Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro.

Hematology (Amsterdam, Netherlands)

Schmetzer HM, Rapp L, Wilmanns W, Gerhartz HH.
PMID: 27406722
Hematology. 1997;2(1):11-9. doi: 10.1080/10245332.1997.11746315.

Myelodysplastic syndromes (MDS) are a heterogenous group of stem cell disorders characterized by an impaired differentiation of the pluripotent stem cell resulting in dysplastic changes of all three hemopoietic lineages. We studied the effect of vitamin D (Vit.D) or...

Cite
Schmetzer HM, Rapp L, Wilmanns W, et al. Effect of GM-CSF, 1, 25-Dihydroxycholecalciferol (Vit.D) and All-Trans-Retinoic Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro. Hematology. 1997;2(1):11-9doi: 10.1080/10245332.1997.11746315.
Schmetzer, H. M., Rapp, L., Wilmanns, W., & Gerhartz, H. H. (1997). Effect of GM-CSF, 1, 25-Dihydroxycholecalciferol (Vit.D) and All-Trans-Retinoic Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro. Hematology (Amsterdam, Netherlands), 2(1), 11-9. https://doi.org/10.1080/10245332.1997.11746315
Schmetzer, H M, et al. "Effect of GM-CSF, 1, 25-Dihydroxycholecalciferol (Vit.D) and All-Trans-Retinoic Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro." Hematology (Amsterdam, Netherlands) vol. 2,1 (1997): 11-9. doi: https://doi.org/10.1080/10245332.1997.11746315
Schmetzer HM, Rapp L, Wilmanns W, Gerhartz HH. Effect of GM-CSF, 1, 25-Dihydroxycholecalciferol (Vit.D) and All-Trans-Retinoic Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro. Hematology. 1997;2(1):11-9. doi: 10.1080/10245332.1997.11746315. PMID: 27406722.
Copy Download .nbib Format: NLM
Distinctive Pattern of Expression of Activation and Resting B Cell Antigens on Normal and Neoplastic Human B Cells: Immunophenotypic Heterogeneity in Some Lymphomas.

Leukemia & lymphoma

Kiyokawa N, Kokai Y, Kikuchi K, Fujita H, Hata J, Fujimoto J.
PMID: 27457297
Leuk Lymphoma. 1990;3(2):119-26. doi: 10.3109/10428199009050985.

The pattern of expression of four B cell antigen systems on mature human B cells and B cell lymphomas were studied. The L30 antigen was detected on small resting B cells, while the B cell activation antigens, CD10, CD25...

Cite
Kiyokawa N, Kokai Y, Kikuchi K, et al. Distinctive Pattern of Expression of Activation and Resting B Cell Antigens on Normal and Neoplastic Human B Cells: Immunophenotypic Heterogeneity in Some Lymphomas. Leuk Lymphoma. 1990;3(2):119-26doi: 10.3109/10428199009050985.
Kiyokawa, N., Kokai, Y., Kikuchi, K., Fujita, H., Hata, J., & Fujimoto, J. (1990). Distinctive Pattern of Expression of Activation and Resting B Cell Antigens on Normal and Neoplastic Human B Cells: Immunophenotypic Heterogeneity in Some Lymphomas. Leukemia & lymphoma, 3(2), 119-26. https://doi.org/10.3109/10428199009050985
Kiyokawa, N, et al. "Distinctive Pattern of Expression of Activation and Resting B Cell Antigens on Normal and Neoplastic Human B Cells: Immunophenotypic Heterogeneity in Some Lymphomas." Leukemia & lymphoma vol. 3,2 (1990): 119-26. doi: https://doi.org/10.3109/10428199009050985
Kiyokawa N, Kokai Y, Kikuchi K, Fujita H, Hata J, Fujimoto J. Distinctive Pattern of Expression of Activation and Resting B Cell Antigens on Normal and Neoplastic Human B Cells: Immunophenotypic Heterogeneity in Some Lymphomas. Leuk Lymphoma. 1990;3(2):119-26. doi: 10.3109/10428199009050985. PMID: 27457297.
Copy Download .nbib Format: NLM
CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration.

Frontiers in immunology

Uetz-von Allmen E, Samson GPB, Purvanov V, Maeda T, Legler DF.
PMID: 34603281
Front Immunol. 2021 Sep 16;12:702453. doi: 10.3389/fimmu.2021.702453. eCollection 2021.

Dendritic cells (DCs) are potent and versatile professional antigen-presenting cells and central for the induction of adaptive immunity. The ability to migrate and transport peripherally acquired antigens to draining lymph nodes for subsequent cognate T cell priming is a...

Cite
Uetz-von Allmen E, Samson GPB, Purvanov V, et al. CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration. Front Immunol. 2021;12:702453doi: 10.3389/fimmu.2021.702453.
Uetz-von Allmen, E., Samson, G. P. B., Purvanov, V., Maeda, T., & Legler, D. F. (2021). CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration. Frontiers in immunology, 12702453. https://doi.org/10.3389/fimmu.2021.702453
Uetz-von Allmen, Edith, et al. "CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration." Frontiers in immunology vol. 12 (2021): 702453. doi: https://doi.org/10.3389/fimmu.2021.702453
Uetz-von Allmen E, Samson GPB, Purvanov V, Maeda T, Legler DF. CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration. Front Immunol. 2021 Sep 16;12:702453. doi: 10.3389/fimmu.2021.702453. eCollection 2021. PMID: 34603281; PMCID: PMC8482423.
Copy Download .nbib Format: NLM
The diagnostic profile of rare acute myelomegakaryoblastic leukemia.

Leukemia & lymphoma

Xu DM, Yu WJ, Xie L, Zhang ZW, Qiu JF, Xu CW, He CL, Xu XR, Xu JS, Li Q, Yin J.
PMID: 34477034
Leuk Lymphoma. 2021 Dec;62(13):3204-3211. doi: 10.1080/10428194.2021.1955878. Epub 2021 Sep 03.

Acute myelomagakaryocytic leukemia is a diagnostic and therapeutic challenge owing to its heterogeneity and overlapping features with other types of acute leukemia. In order to build a diagnostic profile, we analyzed the biological, clinical and hematologic characteristics of acute...

Cite
Xu DM, Yu WJ, Xie L, et al. The diagnostic profile of rare acute myelomegakaryoblastic leukemia. Leuk Lymphoma. 2021;62(13):3204-3211doi: 10.1080/10428194.2021.1955878.
Xu, D. M., Yu, W. J., Xie, L., Zhang, Z. W., Qiu, J. F., Xu, C. W., He, C. L., Xu, X. R., Xu, J. S., Li, Q., & Yin, J. (2021). The diagnostic profile of rare acute myelomegakaryoblastic leukemia. Leukemia & lymphoma, 62(13), 3204-3211. https://doi.org/10.1080/10428194.2021.1955878
Xu, Da-Ming, et al. "The diagnostic profile of rare acute myelomegakaryoblastic leukemia." Leukemia & lymphoma vol. 62,13 (2021): 3204-3211. doi: https://doi.org/10.1080/10428194.2021.1955878
Xu DM, Yu WJ, Xie L, Zhang ZW, Qiu JF, Xu CW, He CL, Xu XR, Xu JS, Li Q, Yin J. The diagnostic profile of rare acute myelomegakaryoblastic leukemia. Leuk Lymphoma. 2021 Dec;62(13):3204-3211. doi: 10.1080/10428194.2021.1955878. Epub 2021 Sep 03. PMID: 34477034.
Copy Download .nbib Format: NLM
Isolation and Characterization of Multipotent Canine Urine-Derived Stem Cells.

Stem cells international

Xu Y, Zhang T, Chen Y, Shi Q, Li M, Qin T, Hu J, Lu H, Liu J, Chen C.
PMID: 33061993
Stem Cells Int. 2020 Sep 30;2020:8894449. doi: 10.1155/2020/8894449. eCollection 2020.

Current cell-based therapies on musculoskeletal tissue regeneration were mostly determined in rodent models. However, a direct translation of those promising cell-based therapies to humans exists a significant hurdle. For solving this problem, canine has been developed as a new...

Cite
Xu Y, Zhang T, Chen Y, et al. Isolation and Characterization of Multipotent Canine Urine-Derived Stem Cells. Stem Cells Int. 2020;2020:8894449doi: 10.1155/2020/8894449.
Xu, Y., Zhang, T., Chen, Y., Shi, Q., Li, M., Qin, T., Hu, J., Lu, H., Liu, J., & Chen, C. (2020). Isolation and Characterization of Multipotent Canine Urine-Derived Stem Cells. Stem cells international, 20208894449. https://doi.org/10.1155/2020/8894449
Xu, Yan, et al. "Isolation and Characterization of Multipotent Canine Urine-Derived Stem Cells." Stem cells international vol. 2020 (2020): 8894449. doi: https://doi.org/10.1155/2020/8894449
Xu Y, Zhang T, Chen Y, Shi Q, Li M, Qin T, Hu J, Lu H, Liu J, Chen C. Isolation and Characterization of Multipotent Canine Urine-Derived Stem Cells. Stem Cells Int. 2020 Sep 30;2020:8894449. doi: 10.1155/2020/8894449. eCollection 2020. PMID: 33061993; PMCID: PMC7545436.
Copy Download .nbib Format: NLM
Interdigitating Reticulum Cell Sarcoma Positive immunohistochemistry for HLA-DR and two other activation antigens, CD30(Ki-1) and CD25(IL2R).

Leukemia & lymphoma

Papadimitriou CS, Bai MC, Stephanou DG, Pavlidis NA, Athanasiadou SE.
PMID: 27467676
Leuk Lymphoma. 1991;4(5):411-7. doi: 10.3109/10428199109068094.

This communication reports a case of the rare interdigitating reticulum cell (IDRC) sarcoma of lymph nodes in a 46-year-old man. Extensive immunophenotypic analysis on paraffin and frozen sections revealed positivity on the neoplastic cells for protein S-100 as well...

Cite
Papadimitriou CS, Bai MC, Stephanou DG, et al. Interdigitating Reticulum Cell Sarcoma Positive immunohistochemistry for HLA-DR and two other activation antigens, CD30(Ki-1) and CD25(IL2R). Leuk Lymphoma. 1991;4(5):411-7doi: 10.3109/10428199109068094.
Papadimitriou, C. S., Bai, M. C., Stephanou, D. G., Pavlidis, N. A., & Athanasiadou, S. E. (1991). Interdigitating Reticulum Cell Sarcoma Positive immunohistochemistry for HLA-DR and two other activation antigens, CD30(Ki-1) and CD25(IL2R). Leukemia & lymphoma, 4(5), 411-7. https://doi.org/10.3109/10428199109068094
Papadimitriou, C S, et al. "Interdigitating Reticulum Cell Sarcoma Positive immunohistochemistry for HLA-DR and two other activation antigens, CD30(Ki-1) and CD25(IL2R)." Leukemia & lymphoma vol. 4,5 (1991): 411-7. doi: https://doi.org/10.3109/10428199109068094
Papadimitriou CS, Bai MC, Stephanou DG, Pavlidis NA, Athanasiadou SE. Interdigitating Reticulum Cell Sarcoma Positive immunohistochemistry for HLA-DR and two other activation antigens, CD30(Ki-1) and CD25(IL2R). Leuk Lymphoma. 1991;4(5):411-7. doi: 10.3109/10428199109068094. PMID: 27467676.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries